Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Travere Therapeutics, Inc.

https://travere.com/

Latest From Travere Therapeutics, Inc.

Finance Watch: SPAC Spree To Continue ‘For Foreseeable Future’

Public Company Edition: Merging with a special purpose acquisition corporation may be an attractive alternative to an initial public offering, but February’s vigorous IPO pace includes seven recent offerings that raised $480.8m in the US. Also, Cassava raised $200m and KalVista brought in $222.5m.

Financing Deals

Retrophin Bolsters Portfolio With Orphan Technologies Buyout

The rare disease-focused firm will pay $90m up front to acquire Orphan Technologies and its Phase I/II enzyme replacement therapy for homocystinuria. Earnouts up to $427m are possible as well.

Deals M & A

Finance Watch: Four Offerings In One Week As Biopharma Keeps Its IPO Market Lead

Lantern, Avidity, Generation Bio and Vaxcyte launched initial public offerings during the second week of June as biopharma continues to intrigue IPO investors. Also, Blackstone invested $350m in Reata's bardoxolone and Checkmate’s $85m series C led recent VC deals. 

Financing Business Strategies

Interview: The Pace Quickens For Calliditas's Berger's Disease Candidate

A Phase III trial design change could result in quicker patient access for Calliditas’s product candidate for Berger’s disease, and boost the growth potential for the Swedish biotech.

Immune Disorders Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Desert Gateway, Inc.
    • Kyalin Biosciences, Inc.
    • Manchester Pharmaceuticals LLC.
    • Orphan Technologies Ltd.
    • Retrophin, Inc.
UsernamePublicRestriction

Register